GLOBAL X ETF ICAV Shareholder Notice - GNOM LN

GLOBAL X ETFS ICAV

(an umbrella fund with segregated liability between sub-funds)

10 Earlsfort Terrace

Dublin 2 D02 T380

Ireland

​

This document is important and requires your immediate attention. If you are in any doubt as to the action you should take, you should seek advice from your investment consultant or other professional advisors.

This document has not been reviewed by the Central Bank of Ireland (the "Central Bank").

If you have sold or transferred all of your shares in Global X Genomics UCITS ETF please pass this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.

Capitalised terms used herein shall bear the same meaning as defined in the prospectus of Global X ETFs ICAV (the "ICAV") dated 26 March 2025 (the "Prospectus") and the supplement to the Prospectus for the purpose of offering shares in Global X Genomics UCITS ETF (the "Supplement"). Copies of the Prospectus and Supplement are available upon request during normal business hours from the registered office of the ICAV.

25 April 2025

RE:    Global X Genomics UCITS ETF (the "Fund") - Index Enhancement

Dear Investors,

The ICAV is an open-ended investment vehicle with variable capital organised under the laws of Ireland and is authorised by the Central Bank pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended.  The Fund is a sub-fund of the ICAV.

We wish to notify you that Solactive AG, the Index Provider (the "Index Provider") of the Fund has enhanced the indexes thematic coverage by increasing the number of constituents from 40 to 50 and allowing the inclusion of pre-revenue and diversified companies alongside existing pure players. The Index Provider has made this adjustment to ensure the index evolves with industry trends, maintaining its relevance and accuracy as thematic industries often require methodological updates to reflect shifting market dynamics. To maintain balance, the weights of diversified players will be capped at an aggregate 10%, with an individual weight limit of 2% (the "Index Enhancements"). Details of the Index Enhancements are set out in the Appendix.

The Supplement of the Fund has been amended to include the Index Enhancements, and it is expected that the Supplement will be noted on or about the 9 May 2025, subject to the Central Bank of Ireland approval. A copy of the revised Supplement will be available upon request during normal business hours from the ICAV or from the local representative of the ICAV in any jurisdiction in which the ICAV is registered for public distribution.

Should you have any questions relating to the changes detailed above, you should contact your local agent, or (if none) Global X ETFs on +44 (0)20 4529 2551 or [email protected], or alternatively you should contact your investment consultant, tax adviser and/or legal adviser as appropriate.

Yours faithfully,

_______________

Director

For and on behalf of

Global X ETFs ICAV

Appendix

Proposed Changes to the Index Guideline

The following Methodology changes are proposed in the following points of the Index Guideline  (ordered in accordance with the numbering of the affected sections):

2.2. SELECTION of the Index Components

From:

4)   Companies are only eligible if they generate at least 50% of their revenues from Genomics related business operations and/or are classified as "Biotechnology" according to the FactSet Industries and Economic Sectors classification system. Genomics business operations include the following: (i) gene editing (ii) genomic sequencing (iii) development and testing of genetic medicine/therapies, and/or (iv) computational genomics and genetic diagnostics. If a company is a potential candidate for inclusion as a result of its classification as "Biotechnology", its exposure to the field of Genomics is further reviewed and confirmed by analyzing the company's R&D expenditures, product pipeline, and operating business segments. The remaining companies are ranked by their INDEX Score, and the 40 highest ranking companies are determined as the final INDEX constituents.

To:

4)   Each company is then classified as follows according to the extent to which it generates revenues from relevant activities:

1.   Pure-Play: Derives at least 50% of revenues from Genomics Activities.

2.   Pre-Revenue: Has primary business operations in Genomics Activities but does not currently generate revenues.

3.   Diversified: Derives revenues from Genomics Activities but less than 50%.

Genomics business operations include but are not limited to the following: (i) gene editing (ii) genomic sequencing (iii) development and testing of genetic medicine/therapies, and/or (iv) computational genomics and genetic diagnostics. The remaining companies are ranked by their Index Score:

1.   The 20 highest ranking Pure-Play/Pre-Revenue companies are added as final Index constituents.

2.   The 5 highest Diversified companies are added as final Index constituents.

3.   Current Index constituents that fulfill the following requirements are added as Index constituents by priority of their weight as of the SELECTION DAY until there are a maximum of 50 Index constituents:

i)          The INDEX constituent has an INDEX Score.

ii)         The INDEX constituent satisfies the INDEX COMPONENT REQUIREMENTS.

iii)        If the total number of Index constituents is still below 50 after the previous steps, companies that satisfy the index universe requirements are added as Index constituents according to their INDEX Score, until there are a maximum of 50 Index constituents. Diversified INDEX constituents will be capped at 10 Index constituents.

From:

5) If there are two or more companies that share the last rank, then preference is given to the company with the highest average daily volume over the last 6 months.

For any future selection the following buffer rules apply:

A) A company that is currently in the INDEX is only excluded if it does not meet the index universe requirements, have a positive INDEX Score anymore, or generates less than 50% of its revenues from Genomics related business operations and/or is no longer classified as "Biotechnology".

B) If there are 40 constituents as of the selection day, a new company is only added if its INDEX Score ranks 10th or higher and derives at least 50% of its revenue from Genomics and/or is classified as "Biotechnology" and passes the additional analysis. In this case, the last ranking company of the current selection is removed

To:

5) If there are two or more companies that share the last rank, then preference is given to the company with the highest market capitalization.

2.3. WEIGHTING OF THE INDEX COMPONENTS

From:

Each INDEX COMPONENT of the Solactive Genomics INDEX is weighted according to Free Float Market Capitalization subject to the following constraints:

1)   The maximum weight of a company is 4.0%.

2)   The maximum weight of a company that has a Market Capitalization larger than USD 50 bn is 2.0%.

3)   The minimum weight of a company is 0.3%.

4)   If a company was subject to the constraint b) on the previous Selection Day and its Market Capitalization is not below USD 40 bn on the current Selection Day, then the maximum weight of the company is 2.0%. The excess weight that results from implementing these constraints is redistributed proportionally such that none of the above constraints are breached.

To:

Each Index Component of the Solactive Genomics Index is weighted according to Free Float Market Capitalization subject to the following constraints:

1)    The maximum weight of a company is 4.0%.

2)    The aggregate weight of Diversified companies cannot exceed 10% of the index weight, and the maximum weight of a Diversified company is 2%.

The excess weight that results from implementing these constraints is redistributed proportionally such that none of the above constraints are breached.

MI208/001/AC#50536405.2

Registered Office: as above

Registration Number: C435449

Directors: Mr. Feargal Dempsey, Ms. Mary Canning and Mr. Robert Oliver (UK)